- York House Church Lane, Chalfont St Peter,
Gerrards Cross, Buckinghamshire, SL9 9RE - 666-888-0000
- info@tersanpharm.com
- info@tersanpharm.com
- York House Church Lane, Chalfont St Peter,
Gerrards Cross, Buckinghamshire, SL9 9RE - Contact Us
May2021
Tersan appoints pharmaceutical industry drug development veteran
Prior to joining Ariana, Hichem was Director of Development Operations at Sanofi. Hichem’s significant achievements encompass multiple therapeutic areas
May2021
Tersan announces an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi
The ATRACTion project will generate clinical, multi-omic (single cell RNA expression, gut microbiota) and additional immunological data by investigating several auto-immune diseases.
May2021
Tersan Announces Appointment of Accomplished Business and Strategy Executive, Kia Motesharei to its Board of Directors.
Dr. Motesharei brings over 20 years of experience in management, strategy, business development, alliance management, product development and marketing across the biotechnology and pharmaceutical industry.
Apr2020
Towards a first precision medicine treatment of Alzheimer’s disease using Tersan’s Explainable AI.
Paris and Boston, April 17th 2020. Tersan® Pharma, a leading digital health company announced today the publication of the first reported genome-wide search for biomarkers associated with drug response in Alzheimer’s disease in the Alzheimer’s & Dementia: Translational Research & Clinical Interventions journal. Using Tersan’s proprietary KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, […]
Nov2019
Comorbidities play an important role in hospitalized influenza mortality risk, Real World Evidence (RWE) study performed by Tersan and Sanofi Pasteur shows
Big Data analysis of over 125 Million patient hospitalization records using Tersan’s data analytics and AI platform identifies significant factors increasing Case Fatality Rates Paris and Boston, November 7th 2019. Tersan Pharmaceuticals Ltd, a leading digital health Company announced the publication of an influenza Real World analysis in collaboration with Sanofi-Pasteur. Influenza-related mortality for hospitalized patients […]
Sep2019
Towards a first precision medicine Immunotherapy for the treatment of Type 1 Diabetes using Tersan’s Artificial Intelligence
Tersan’s KEM® Artificial Intelligence technology identified immunological changes, which are early indicators of clinical effects, for selected groups of patients in a first-in-human Phase 1b study. The potential for a selection biomarker in patients receiving this therapy transforms design options for Imcyse’s future clinical trials in T1D and additional indications. On August 27th 2019, Imcyse, […]
Mar2019
Colon Cancer and combination therapy: Tersan to present data at AACR 2019 using its AI technology and PDX mouse model simulated clinical trial
Tersan to present data at AACR 2019 on using its KEM® Artificial Intelligence technology and PDX mouse models to simulate patient stratification in clinical trials and Identify companion biomarkers for combination therapy Tersan Pharmaceuticals Ltd, a leading digital health Company focused on developing advanced therapeutic decision support systems, will present its latest results on combination therapy […]
Oct2018
Tersan’s AI provides evidence for 3 years clinical efficacy of ANAVEX®2-73 Alzheimer’s targeted therapy @CTAD2018
Precision medicine approach using Tersan’s AI KEM® shows that a small data rich open label clinical study of 32 well-characterized patients may be sufficient to identify strong biomarker hypothesis identifying patients with the highest chance of benefiting from the drug. BARCELONA, October 26th, 2018. Dr Mohammad Afshar presented 3 years longitudinal data of clinical […]
Oct2018
Tersan Pharmaceuticals Ltd helps Valiseek® demonstrate efficacy of its lung cancer therapy in phase 2 clinical trial
Tersan Pharmaceuticals Ltd helps Valiseek® demonstrate efficacy of its lung cancer therapy in phase 2 clinical trial. Tersan®’s KEM® data analysis shows positive results for ValiSeek VAL401 in Phase II trial for non-small cell lung cancer (NSCLC) patients. Tersan’s KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, shows that patients receiving the VAL401 treatment […]
Oct2018
Gastric Cancer: Artificial Intelligence helps identify novel single biomarkers to guide targeted precision medicine
Gastric Cancer: Tersan and academic collaborators from the Gastro Glyco Explorer consortium identify a novel single marker for Microsatellite instability (MSI), a distinct molecular subtype of gastric cancer. Gastric cancer is the second most common cause of cancer-related deaths in the world. Adapting the therapeutic choice to the molecular diversity of the disease is a […]